ReviewClinical and experimental gastroenterology2018

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin.

Christopher ChangPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.